Key result
NYHA III/IV DCM linked to ~2.7-fold higher annual societal costs.
Why the study?
Dilated cardiomyopathy poses a substantial economic burden on society and affects quality of life, but respective data are missing.
Cross-Sectional (n=550)
Dilated cardiomyopathy imposes a substantial economic and quality-of-life burden, which significantly worsens in patients with more advanced disease stages.
Answers are grounded in this paper and cite their sources.
DCM carries substantial QoL and societal costs; extends sparse data but leaves open need for longitudinal studies before guiding care.
Background/Introduction Dilated cardiomyopathy (DCM) is a major cause of heart failure and can be associated with events like arrhythmias, syncope or sudden cardiac death. Next to the physical disease burden and the mental strain for patients, DCM also poses a substantial economic burden on society; however, respective data is missing. Purpose This study aims to measure the quality of life (QoL) and societal costs of DCM patients. Methods A cross-sectional evaluation of QoL and societal costs of DCM patients was performed through the 5-level EuroQol (EQ-5D-5L) and the Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ), respectively. QoL was translated into numerical values (i.e. utilities) for statistical analysis. Costs were measured from a Dutch societal perspective including medical costs, patient and family costs, productivity losses and costs in other sectors. Final costs were extrapolated to one year, reported in 2022 Euros, and compared between DCM severity according to NYHA classes. Results A total of 550 DCM patients were included. Mean age was 61 years, and 34% were women. Among EQ-5D dimensions, DCM patients scored lowest in usual activities, pain/discomfort and mobility (Figure 1). Overall utility was lower than the Dutch population mean (0.840 vs. 0.869, p = .225). Total societal DCM costs were €14,843 per patient per year (Figure 2). Cost drivers were productivity losses (€7,037) and medical costs (€4,621) due to inpatient care (€2,231), outpatient care (€863) and medication (€805). Patients with more symptomatic DCM (i.e. NYHA class III or IV) had significantly higher average DCM costs per year compared to less symptomatic DCM (€31,099 vs. €11,446, p < .001) and significantly lower utilities (0.631 vs. 0.883, p < .001). Conclusion DCM is associated with reduced QoL and high societal costs, especially in more advanced disease stages. To our knowledge, this is the first study describing the economic burden of DCM in the Netherlands. More studies in DCM are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Wiethoff et al. (2023) conducted a cross-sectional in Dilated cardiomyopathy (n=550). More symptomatic DCM (NYHA class III or IV) vs. Less symptomatic DCM was evaluated on Average DCM costs per year (p=<.001). More symptomatic dilated cardiomyopathy (NYHA III/IV) was associated with higher average annual societal costs compared to less symptomatic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: